公开(公告)号：US07351695B2

公开(公告)日：2008-04-01

申请号：US10716976

申请日：2003-11-19

申请人： Öm Almarssoo ,  Jules Remenar ,  Matthew L. Peterson

发明人： Öm Almarssoo ,  Jules Remenar ,  Matthew L. Peterson

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K9/24

CPC分类号： A61K9/1652 ,  A61K9/0014 ,  A61K9/0019 ,  A61K47/10 ,  A61K47/32 ,  C07H5/04 ,  C07H5/06

摘要： The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.

摘要翻译： 本发明包括托吡酯及其药学上可接受的多晶型物，溶剂合物，水合物，脱水剂，共晶体，无水或无定形形式的新型盐以及含有该盐的药物组合物和药物单位剂型。 特别地，本发明包括托吡酯的药学上可接受的盐，包括但不限于托吡酯钠，托吡酯锂，托吡酯钾或多晶型物，溶剂合物，水合物，脱水剂，共晶体，无水和无定形形式。 本发明还包括托吡酯的新型共晶体或络合物，以及包含它们的药物组合物。 本发明还包括治疗或预防各种疾病和病症的方法，包括但不限于癫痫发作，癫痫病症，震颤，脑功能障碍，肥胖症，神经性疼痛，情感障碍，戒烟，偏头痛和丛集性头痛。

公开(公告)号：US06559293B1

公开(公告)日：2003-05-06

申请号：US10232589

申请日：2002-09-03

申请人： Örn Almarsson ,  Jules Remenar ,  Matthew L. Peterson

发明人： Örn Almarsson ,  Jules Remenar ,  Matthew L. Peterson

IPC分类号： C07H504

CPC分类号： A61K9/1652 ,  A61K9/0014 ,  A61K9/0019 ,  A61K47/10 ,  A61K47/32 ,  C07H5/04 ,  C07H5/06

摘要： The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.

摘要翻译： 本发明包括托吡酯及其药学上可接受的多晶型物，溶剂合物，水合物，脱水剂，共晶体，无水或无定形形式的新型盐以及含有该盐的药物组合物和药物单位剂型。 特别地，本发明包括托吡酯的药学上可接受的盐，包括但不限于托吡酯钠，托吡酯锂，托吡酯钾或多晶型物，溶剂合物，水合物，脱水剂，共晶体，无水和无定形形式。 本发明还包括托吡酯的新型共晶体或络合物，以及包含它们的药物组合物。 本发明还包括治疗或预防各种疾病和病症的方法，包括但不限于癫痫发作，癫痫病症，震颤，脑功能障碍，肥胖症，神经性疼痛，情感障碍，戒烟，偏头痛和丛集性头痛。

公开(公告)号：US07078526B2

公开(公告)日：2006-07-18

申请号：US10449307

申请日：2003-05-30

申请人： Jules Remenar ,  Michael MacPhee ,  Matthew Lynn Peterson ,  Sherry Lynn Morissette ,  Orn Almarsson

发明人： Jules Remenar ,  Michael MacPhee ,  Matthew Lynn Peterson ,  Sherry Lynn Morissette ,  Orn Almarsson

IPC分类号： C07D407/14 ,  A61K31/496 ,  A61P31/10

CPC分类号： A61K9/0014 ,  A61K9/1652 ,  A61K47/10 ,  A61K47/32 ,  C07D405/14

摘要： The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.

摘要翻译： 本发明提供了可用作药物的盐，共晶和相关溶剂合物的新型可溶性唑型结晶形式（例如伊曲康唑，泊沙康唑和沙伯康唑）。 本发明还提供药物组合物，其包含和制备这些唑型结晶形式。 还提供了使用这些组合物来治疗或预防全身和局部真菌，酵母和皮肤癣菌感染的方法。